Smoking Weakens Heart Structure and Function: Study

Sep.01.2022
Smoking Weakens Heart Structure and Function: Study
Smoking weakens the heart's structure and function, but quitting can help it recover, according to researchers from Denmark.

Researchers from Herlev and Gentofte Hospitals in Copenhagen have found that smoking weakens the structure of the heart, affecting its function. The research team also found that quitting smoking helps the heart to recover.


Previous research has indicated that over 30% of deaths are caused by coronary heart disease, with active smoking or exposure to secondhand smoke as reliable sources of exposure. Smoking increases the risk of heart attack by twice as much and the risk of stroke by three times as much.


Researchers from Herlev and Gentofte Hospital in Copenhagen, Denmark, have found evidence that smoking not only affects a person's blood vessels, but also weakens the structure of the heart itself, thereby impacting its functioning.


Researchers recently presented their findings at the 2022 European Society of Cardiology (ESC) Congress.


Past studies have shown that smoking has negative effects on a person's blood vessels, which may lead to heart issues. For example, nicotine found in cigarettes can cause the blood vessels to narrow, limiting the amount of blood that can flow through them. Nicotine can also significantly increase a person's blood pressure. "We know that smoking can cause coronary artery disease and heart failure," explained Dr. Eva Holt, the main author of the study and a researcher from Herlev and Gentofte Hospital in Copenhagen, Denmark. "But the purpose of this study is to investigate whether smoking has an independent effect on the heart structure and function of a large population of ordinary people without known heart disease," she pointed out.


Dr. Halt and her team evaluated data from over 3,800 participants in the fifth Copenhagen City Heart Study in order to ensure its reliability. The study examined cardiovascular disease and risk factors in the general population. Participants ranged in age from 20 to 93 and had no history of heart disease. Data collected during the study included a questionnaire about smoking history among participants, as well as reliable sources of echocardiography or heart ultrasound.


Researchers have determined that current smokers in the participant pool have hearts that are thicker, heavier, and weaker compared to those who have never smoked. "We found that current and accumulated pack-years were associated with structural and functional deterioration of smoking-related left ventricle, the heart's most important part," said Dr. Holt. "Additionally, we found that over 10 years, those who continue to smoke have hearts that become even thicker, heavier, and weaker, resulting in a poorer ability to pump blood, compared to those who have never smoked or quit during that period.


MNT spoke with Dr. Rigved Tadwalkar, a certified cardiologist at the Providence Saint John's Health Center in Santa Monica, California, who did not participate in the study. "What's interesting about this study is that it focuses on the changes in the left ventricle of the heart, which have not been well understood so far, due to tobacco use," he commented. "We always talk about the link between tobacco use and vascular diseases (including coronary heart disease), but we haven't really delved into the details of how tobacco affects the structure and function of the heart itself," he pointed out.


According to Dr. Tadwalkar, smoking increases the tendency for plaque formation in the arterial walls, which is clinically referred to as a reliable source of atherosclerosis. He stated that this may directly or indirectly lead to heart damage.


Direct smoking can damage the blood vessel wall, causing constriction and reduced elasticity, as well as impairing the function of the blood vessel's inner layer endothelium," he explained.


According to a new study, Dr. Holt and her team have found evidence that quitting smoking can help the heart recover to some extent. "After quitting smoking, the heart appears to have regained its previous structure and function, which could be a valuable incentive for patients to quit smoking," she added.


Dr. Tadwalkar stated, "We do indeed have concrete data to support this study, which follows a series of previous studies showing that quitting smoking can improve overall health in multiple ways beyond just the heart.


So the good news is, even immediate action has physiological benefits," he pointed out. "And then, due to the lack of chronic exposure, the reduction of inflammatory burden and these other destructive pathological processes over time is partially the reason for improvement.


Disclaimer: 1. The content of this article is compiled from third-party information and is only intended for industry discussion and learning. 2. This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the content. The compilation of this article is only for industry discussion and research purposes. 3. Due to the limited compiling ability, the compiled article may not fully convey the expression of the original text. Please refer to the original text for accuracy. 4. 2FIRSTS fully supports the Chinese government's position on any domestic, Hong Kong, Macao, and Taiwan-related issues or positions. 5. The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
The U.S. FDA authorized 24 VELO nicotine pouch products from a British American Tobacco subsidiary, raising the total number of authorized products from 43 to 67, a 55.8% increase. The newly authorized 4 mg products include lime and passion fruit flavors and feature certified child-resistant packaging. VELO's first FDA marketing authorization adds BAT to a list previously limited to PMI and Altria products, while bringing the agency's nicotine pouch review pilot total to 47 authorized products.
Oct.30
PMI's IQOS Extends ZAMNA Electronic-Music Partnership to Spain as Vogue España Publishes Branded Content
PMI's IQOS Extends ZAMNA Electronic-Music Partnership to Spain as Vogue España Publishes Branded Content
Philip Morris International's IQOS has extended its partnership with electronic-music event brand ZAMNA to Spain, setting up a House of IQOS at ZAMNA Madrid. Vogue España and Time Out Madrid subsequently published branded content clearly labeled as collaborations with IQOS. PMI has also expanded its company-owned IQOS boutique network in Spain to seven cities this year. The company says IQOS's adjusted heated-tobacco market share in Europe reached 12.6% in the first quarter of 2026, with Spain among its stronger-performing European markets.
Sep.20
Product | Philip Morris Japan Teams Up With Renowned French Audio Brand DEVIALET for Limited-Edition IQOS Priced 60% Above Standard Model
Product | Philip Morris Japan Teams Up With Renowned French Audio Brand DEVIALET for Limited-Edition IQOS Priced 60% Above Standard Model
Philip Morris Japan (PMJ) launched the limited-edition IQOS ILUMA i PRIME Soundsorial Model in collaboration with French audio brand DEVIALET on October 1, 2026. Featuring sound-wave patterns, a silver-and-black finish and a gradient holder, the heated tobacco device is priced at JPY 15,980, including tax, and is available at four IQOS stores in Japan. According to Japanese media citing a PMJ representative, about 1,900 units were allocated to the Japanese retail market. A separate Soundsorial Collection, combining the device with DEVIALET Gemini II earbuds, includes 440 sets allocated to Japan for a membership prize draw.
product
Oct.23
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26